BlackRock Inc. decreased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 0.9% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,084,028 shares of the biopharmaceutical company’s stock after selling 55,242 shares during the period. BlackRock Inc. owned 6.04% of Alnylam Pharmaceuticals worth $532,474,000 at the end of the most recent reporting period.
Other hedge funds also recently modified their holdings of the company. Nelson Van Denburg & Campbell Wealth Management Group LLC bought a new position in Alnylam Pharmaceuticals during the 2nd quarter valued at $137,000. Opera Trading Capital bought a new position in Alnylam Pharmaceuticals during the 3rd quarter valued at $137,000. Mutual of America Capital Management LLC lifted its position in shares of Alnylam Pharmaceuticals by 98.5% in the 2nd quarter. Mutual of America Capital Management LLC now owns 1,935 shares of the biopharmaceutical company’s stock worth $191,000 after buying an additional 960 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its position in shares of Alnylam Pharmaceuticals by 600.9% in the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,278 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 1,953 shares during the last quarter. Finally, IPG Investment Advisors LLC bought a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter worth about $217,000. 88.46% of the stock is owned by hedge funds and other institutional investors.
ALNY stock opened at $74.38 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 10.96 and a current ratio of 11.05. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $63.57 and a fifty-two week high of $153.99. The stock has a market capitalization of $7.92 billion, a P/E ratio of -13.72 and a beta of 2.54.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($2.43) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($2.02) by ($0.41). Alnylam Pharmaceuticals had a negative return on equity of 43.07% and a negative net margin of 754.13%. The firm had revenue of $2.07 million during the quarter, compared to analyst estimates of $22.66 million. During the same period last year, the business earned ($1.34) EPS. The firm’s revenue was down 87.9% on a year-over-year basis. As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -7.75 earnings per share for the current fiscal year.
A number of research analysts have recently issued reports on ALNY shares. Zacks Investment Research downgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, October 8th. BidaskClub downgraded shares of Alnylam Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, October 24th. Leerink Swann started coverage on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 27th. They issued a “market perform” rating and a $63.00 price target on the stock. ValuEngine downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 21st. Finally, BMO Capital Markets restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, October 18th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and thirteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $138.44.
COPYRIGHT VIOLATION WARNING: “Alnylam Pharmaceuticals, Inc. (ALNY) Shares Sold by BlackRock Inc.” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/12/08/alnylam-pharmaceuticals-inc-alny-shares-sold-by-blackrock-inc.html.
Alnylam Pharmaceuticals Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Featured Story: How Buying a Call Option Works
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.